Local Thermal Ablation with Continuous EGFR Tyrosine Kinase Inhibitors for EGFR-Mutant Non-small Cell Lung Cancers that Developed Extra-Central Nervous System (CNS) Oligoprogressive Disease-Reference-Cited by-同舟云学术

Local Thermal Ablation with Continuous EGFR Tyrosine Kinase Inhibitors for EGFR-Mutant Non-small Cell Lung Cancers that Developed Extra-Central Nervous System (CNS) Oligoprogressive Disease

Published:2019-01-30 Issue:5 Volume:42 Page:693-699
ISSN:0174-1551
Container-title:CardioVascular and Interventional Radiology
language:en
Short-container-title:Cardiovasc Intervent Radiol

Author:

Ni Yang,Liu Baodong,Ye Xin,Fan Weijun,Bi Jingwang,Yang Xia,Huang Guanghui,Li Wenhong,Wang Jiao,Han Xiaoying,Wei Zhigang,Meng Min

Funder

National Natural Science Foundation of China

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine,Radiology Nuclear Medicine and imaging

Link

http://link.springer.com/article/10.1007/s00270-018-02153-x/fulltext.html

Reference34 articles.

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.

2. Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, Aronson SL, Su PF, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311(19):1998–2006.

3. Sequist LV, Yang JC, Yamamoto N, O’Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327–34.

4. Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu CP, O’Byrne K, Feng J, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015;16(2):141–51.

5. Wu YL, Zhou C, Liam CK, Wu G, Liu X, Zhong Z, Lu S, Cheng Y, Han B, Chen L, et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label ENSURE study. Ann Oncol. 2015;26(9):1883–9.

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and efficacy of percutaneous cryoablation for primary and metastatic pleural based tumors;European Journal of Radiology;2024-06

2. Efficacy and safety of microwave ablation and its synergistic potential in the treatment of early-stage non-small cell lung cancer;Clinical Imaging;2024-03

3. The Emerging Role of Radiotherapy in Oligoprogressive Non-Small Cell Lung Cancer;Surgical Oncology Clinics of North America;2023-07

4. Prolonged disease control with local treatments in oligo-acquired resistance to immune-checkpoint inhibitors;Translational Lung Cancer Research;2023-06

5. Percutaneous image-guided thermal ablation of lung cancer: What is the evidence?;Lung Cancer;2023-02